以颤三针为主治疗帕金森病的临床研究
|
摘要
研究背景:
帕金森病是一种常见的神经系统变性疾病,也是中老年常见的致残疾患之一,该病的临床表现主要为:运动减少、骨骼肌张力增高和静止时的肌肉震颤。这一组特殊的症状群1817年首先由英国医生巴金森(Parkinson)所描述,故命名为PD。PD在世界各地调查患病率分布极不一致。欧美各国白种人调查患病率为66-187/10万,日本为37-80.6/10万。我国标化率为10.8/10万,世界标化率为15.0/10万,我国帕金森患病率低于西方发达国家。PD很少在40岁之前发生,在不同的临床和病因学研究中,早发和晚发PD主要是以40岁作为确定的界限。很多人群调查表明男性的发病比女性高。
PD的治疗作为12世纪神经科学重要的研究疾病之一,帕金森病(PD)目前尚无办法根治,且早期诊断率较低,各种客观诊断和检测指标还在研究当中、尚不成熟。当前PD治疗的目的主要在于控制临床症状,仍以左旋多巴制剂为主,左旋多巴制剂治疗经2-5年内常出现诸多副作用,如恶心、呕吐、厌食、血压轻度降低、直立性低血压、“剂末现象”、“开关现象”、运动障碍、精神异常等,也有15%左右的病人根本无效,且长期服药则副作用越明显、越重,并且存在疗效减退等。导致很多病人最后无法坚持治疗。为了减小西药毒副作用、增强临床疗效,目前人们越来越重视中医和针灸的治疗方法。临床资料显示针灸在治疗PD方面是行之有效的一种方法,但是目前国内外在此方面的研究却相对较少。
研究目的:
颤三针治疗帕金森的临床研究
研究方法:
将62例患者,随机分为治疗组和对照组,每组31例病人。分别采用颤三针和西药治疗,观察两组患者的临床症状、运动工作、生活质量等方面,来评价两组的治疗效果。
研究结果:
1、治疗结束后,两组除面部表情、吞咽、言语其他各项均得到改善,治疗组疗效优于对照组;两组的面部表情均有改善,两组改善无差异;治疗结束后,言语、吞咽无改善。
2、治疗结束后,两组生活质量均得到改善。治疗组疗效优于对照组。治疗结束后,治疗组临床治愈1例,明显进步16例,进步5例,稍有进步4例,无效5例,总有效率83.87%;对照组临床治愈0例,明显进步9例,进步6例,稍有进步7例,无效9例,总有效率70.96%。经Ridit分析,Z=2.03,P=0.03(P＜0.05),差异有统计学意义。提示:治疗结束后,治疗组疗效优于对照组。
研究结论:
颤三针能够改善帕金森病人的临床症状,提高生活质量。
Background:Parkinson's disease(PD) is a neurological condition that is commonly seen in the elderly,characterized by motor impairment,slowing of physical movement,muscle rigidity,and tremor at rest.The disease is named after the English physician James Parkinson,who made a detailed description of the disease in his essay published in 1817.The prevalence of the disease differs throughout the world.It is most prevalent in Europe and the America,estimated at a rate of 66-187 in 100,000,and Japan at a rate of 37-80.6 in 100,000.The standardized rate in China is 10.8 in 100,000, while that of the world is 15.0 in 100.000.Our rate is far less than the world standard.PD rarely occurs at an age below 40 years old,and the occurrence rate in male is much higher than in female.
At present,there is no cure for PD,researches to discover novel drug to treat PD has put into focus.It is a progressive disorder,which makes early diagnosis difficult.Moreover,many diagnostic measures,such as scans, have yet been standardized.Medications for PD can only provide relief from the symptoms.Currently.levodopa(L-dopa) is the most widely used form of treatment.It is transformed into dopamine in the dopaminergic neurons by L-aromatic amino acid decarboxylase.However,long-term use(2-5 years) of L-dopa may induce numerous side-effects,such as nausea,vomiting,anorexia, low blood pressure,the "end of dose" effect,the "on-off" effect. kinematic impairment,and cognitive and behavioral symptoms.Medication is ineffective in approximately 15%of the patients,and the daily dosage would only worsen the symptoms.In hope to minimize the side effect of oral medication,acupuncture as a complementary treatment has become more recognized for its effectiveness and minimal side-effect.However,limited number of researches has been done to prove its effect in the treatment of PD.
Objective:To investigate the curative effect of using tremor three needles in the treatment of Parkinson's Disease.
Method:A total of sixty PD patients were randomly divided into treatment and control groups,each having 30 patients.The treatment group used acupuncture,mainly tremor three needles,and the control group used mainstream medication(L-dopa).Their clinical symptoms,physical activity, quality of life were observed and recorded before and after treatment.
Results:
1.After treatment,all indeces in the treatment group significantly improved, except for facial expression,swallowing ability and speech,as compared to the control group.The facial expression in both groups improved,but the change in difference between the groups was not significant.As for swallowing and speech,both groups did not improve after treatment.
2.The quality of life significantly improved in the treatment group,as opposed to the control group.After treatment,the treatment group consisted of the following:1 patient clinically recovered,16 extreme improvements,5 moderate improvements,4 slight improvements,5 ineffective:the total effective rate was 83.87%.The control group consisted of 0 patient clinically recovered,9 extreme improvement.6 moderate improvement,7 slight improvement,9 ineffective:the total effective rate was 70.96%.After Ridit anaiysis,Z=2.03,P=0.03(p＜0.05), the change in improvement between the two groups was significant,thus, the treatment group was more effective in the treatment of PD than the control group.
Conclusions:
The use of tremor three needles in the treatment of PD is effective and can improve the patients' symptoms and quality of life.
帕金森病是一种常见的神经系统变性疾病,也是中老年常见的致残疾患之一,该病的临床表现主要为:运动减少、骨骼肌张力增高和静止时的肌肉震颤。这一组特殊的症状群1817年首先由英国医生巴金森(Parkinson)所描述,故命名为PD。PD在世界各地调查患病率分布极不一致。欧美各国白种人调查患病率为66-187/10万,日本为37-80.6/10万。我国标化率为10.8/10万,世界标化率为15.0/10万,我国帕金森患病率低于西方发达国家。PD很少在40岁之前发生,在不同的临床和病因学研究中,早发和晚发PD主要是以40岁作为确定的界限。很多人群调查表明男性的发病比女性高。
PD的治疗作为12世纪神经科学重要的研究疾病之一,帕金森病(PD)目前尚无办法根治,且早期诊断率较低,各种客观诊断和检测指标还在研究当中、尚不成熟。当前PD治疗的目的主要在于控制临床症状,仍以左旋多巴制剂为主,左旋多巴制剂治疗经2-5年内常出现诸多副作用,如恶心、呕吐、厌食、血压轻度降低、直立性低血压、“剂末现象”、“开关现象”、运动障碍、精神异常等,也有15%左右的病人根本无效,且长期服药则副作用越明显、越重,并且存在疗效减退等。导致很多病人最后无法坚持治疗。为了减小西药毒副作用、增强临床疗效,目前人们越来越重视中医和针灸的治疗方法。临床资料显示针灸在治疗PD方面是行之有效的一种方法,但是目前国内外在此方面的研究却相对较少。
研究目的:
颤三针治疗帕金森的临床研究
研究方法:
将62例患者,随机分为治疗组和对照组,每组31例病人。分别采用颤三针和西药治疗,观察两组患者的临床症状、运动工作、生活质量等方面,来评价两组的治疗效果。
研究结果:
1、治疗结束后,两组除面部表情、吞咽、言语其他各项均得到改善,治疗组疗效优于对照组;两组的面部表情均有改善,两组改善无差异;治疗结束后,言语、吞咽无改善。
2、治疗结束后,两组生活质量均得到改善。治疗组疗效优于对照组。治疗结束后,治疗组临床治愈1例,明显进步16例,进步5例,稍有进步4例,无效5例,总有效率83.87%;对照组临床治愈0例,明显进步9例,进步6例,稍有进步7例,无效9例,总有效率70.96%。经Ridit分析,Z=2.03,P=0.03(P＜0.05),差异有统计学意义。提示:治疗结束后,治疗组疗效优于对照组。
研究结论:
颤三针能够改善帕金森病人的临床症状,提高生活质量。
Background:Parkinson's disease(PD) is a neurological condition that is commonly seen in the elderly,characterized by motor impairment,slowing of physical movement,muscle rigidity,and tremor at rest.The disease is named after the English physician James Parkinson,who made a detailed description of the disease in his essay published in 1817.The prevalence of the disease differs throughout the world.It is most prevalent in Europe and the America,estimated at a rate of 66-187 in 100,000,and Japan at a rate of 37-80.6 in 100,000.The standardized rate in China is 10.8 in 100,000, while that of the world is 15.0 in 100.000.Our rate is far less than the world standard.PD rarely occurs at an age below 40 years old,and the occurrence rate in male is much higher than in female.
At present,there is no cure for PD,researches to discover novel drug to treat PD has put into focus.It is a progressive disorder,which makes early diagnosis difficult.Moreover,many diagnostic measures,such as scans, have yet been standardized.Medications for PD can only provide relief from the symptoms.Currently.levodopa(L-dopa) is the most widely used form of treatment.It is transformed into dopamine in the dopaminergic neurons by L-aromatic amino acid decarboxylase.However,long-term use(2-5 years) of L-dopa may induce numerous side-effects,such as nausea,vomiting,anorexia, low blood pressure,the "end of dose" effect,the "on-off" effect. kinematic impairment,and cognitive and behavioral symptoms.Medication is ineffective in approximately 15%of the patients,and the daily dosage would only worsen the symptoms.In hope to minimize the side effect of oral medication,acupuncture as a complementary treatment has become more recognized for its effectiveness and minimal side-effect.However,limited number of researches has been done to prove its effect in the treatment of PD.
Objective:To investigate the curative effect of using tremor three needles in the treatment of Parkinson's Disease.
Method:A total of sixty PD patients were randomly divided into treatment and control groups,each having 30 patients.The treatment group used acupuncture,mainly tremor three needles,and the control group used mainstream medication(L-dopa).Their clinical symptoms,physical activity, quality of life were observed and recorded before and after treatment.
Results:
1.After treatment,all indeces in the treatment group significantly improved, except for facial expression,swallowing ability and speech,as compared to the control group.The facial expression in both groups improved,but the change in difference between the groups was not significant.As for swallowing and speech,both groups did not improve after treatment.
2.The quality of life significantly improved in the treatment group,as opposed to the control group.After treatment,the treatment group consisted of the following:1 patient clinically recovered,16 extreme improvements,5 moderate improvements,4 slight improvements,5 ineffective:the total effective rate was 83.87%.The control group consisted of 0 patient clinically recovered,9 extreme improvement.6 moderate improvement,7 slight improvement,9 ineffective:the total effective rate was 70.96%.After Ridit anaiysis,Z=2.03,P=0.03(p＜0.05), the change in improvement between the two groups was significant,thus, the treatment group was more effective in the treatment of PD than the control group.
Conclusions:
The use of tremor three needles in the treatment of PD is effective and can improve the patients' symptoms and quality of life.
引文
[1]《黄帝内经·素问》.北京:人民卫生出版社,100,138.
[3]孙星衍.校华氏中藏经,第1版.上海:商务印书馆,1956;25.
[4]孙思邈.备急千金要方(影印本)北京:人民卫生出版社,1982;158.
[5]孙一奎.赤水玄珠.北京:人民卫生出版社,1986;1125.
[6]清·张璐.张氏医通.中国中医药出版社,1995;141,268,345,464-465.
[7]王肯堂.证治准绳.北京:人民卫生出版社,1991;435-437,578-580.
[8]王永炎,李明富,戴锡孟,等编.中医内科学[M].上海:上海科学技术出版社.1994;第6版:370.
[9]王亚丽.颤证的病因病机探讨[J].陕西中医学院学报,1995;21(3):5.
[10]朱红梅,震颤麻痹的病理探析[J].厦门大学学报.自然科学版,2000;(64):556-559.
[11]邹忆怀.王永炎.治疗颤振病(帕金森氏病)经验探讨[J].北京中医药大学学报,1996:(19):15.
[12]黄俊山.震颤麻痹辨证体会[J].实用中西医结合杂志,1996:9(1):8.
[13]潘澄镰.震颤麻痹的证治探讨[J].浙江中医杂志.1990:25(11):483.
[14]陈利国.针刺治疗震颇麻痹49例临床观察[J].中医杂志,1996:37(4):217.
[15]崔悦.解郁法为土治疗震颤麻痹12例[J],国医论坛,1993;8(5):37.
[16]王坤山,等.试谈A颤麻痹辨治体会[J],甘肃中医,1993;6(3):9.
[17]周叔平.浅谈震颤麻痹综合征与督脉的关系[J].新中医,1997;29(5):52.
[18]李学文.中医辨证分型治疗震颤麻痹症的临床体会[J].包头医学.2000;24(3):28.
[19]黄文燕,眼针结合中药治疗帕金森病45例[J].上海针灸杂志,2000;19(4):20.
[20]景晓东,张海峰,朗丽辉.定振丸治疗震颤麻痹34例[J].吉林中医药,2000:(1):38.
[21]劳国平.中西医结合治疗震颤麻痹的疗效观察[J].河北中医,2000;22(10):777-778.
[22]陈建宗,江文,史健,等.培补肝肾为主治疗帕金森病临床观察[J].成都中医药大学学,1999:22(3):14-19.
[23]刘尚建.中西医结合治疗老年颤证26例[J].陕西中医,2001;22(3):172.
[24]丰广魁.震颤舒治疗帕金森病30例[J].陕西中医,2000:21(11):481.
[25]郭淑睿,张彩玉,付文玉,等.坎离丸治疗帕金森病19例[J].辽宁中医杂志,2001;28(3):154-155.
[26]叶中峰.辨证分型治疗震颤麻痹36例[J].四川中医,2001;19(10):30.
[27]祝维峰.震颤宁与美多巴合用治疗帕金森病40例[J].中国民间疗法,2000:8(7):35-36.
[28]张健.中药治疗帕金森氏综合征30例[J].中医药信息,2000:(3):73.
[29]王建国,罗文辉.唐世清.乌龙汤治疗震颤麻痹22例小结[J].湖南中医杂志,2000;16(1):13-14.
[30]陈建宗,陈晓莉,李军昌.培补肝肾法治疗帕金森病40例临床观察[J].中医药研究,1998:14(3):10.
[31]樊奎.周仲瑛.治疗震颤麻痹的经验[J].中医杂志,1996;37(11):63-64.
[32]王克勤.震颤麻痹的中医治疗[J].中医药研究,199l;(2):35.
[33]刘明武.震颤麻痹辨治探幽[J].辽宁中医杂志,1997;24(11):490.
[34]曾宪贵.育阴活络汤治疗四肢震颤4例[J].辽宁中医杂志,1990;17(6):16.
[35]王瑞海.震颤证临床治疗概述[J].山东中医杂志,1990;9(1):57.
[36]潘文奎.小议帕金森氏病的证治思路[J].中医药研究,1995:(6):9.
[37]黄月芳.中西医结合治疗震颤麻痹32例[J].江苏中医,1997,18(9):16.
[38]李双蕾.中西医结合治疗震颤麻痹临床观察[J].广西中医药.1997;20(3):25.
[39]刘华中西医结合治疗帕金森氏病45例[J].浙江中医杂志,1993;28(6):47.
[40]任光兴.熄风汤、安坦治疗帕金森氏病综合征对照观察[J].山东中医杂志,1990:9(2):21.
[41]李玉生.内外结合治疗震颇麻痹42例[J].陕西中医,1993;14(8):348.
[42]丰广魁.邵凤扬,李加兵.中药震颇舒治疗震颇麻痹的疗效分析[J].中国临床康复,2002;6(3):334-335.
[43]黄俊山.震颇麻痹辨证体会[J].实用中西医结合杂志,1996;9(1):8.
[44]王克勤.震颤麻痹的中医治疗[J].中医药研究,1991;(2):35.
[45]黄俊山.震颤麻痹辨治体会[J].实用中西医结合杂志,1996;9(1):8-9.
[46]秦有学.中西医结合治疗震颤麻痹31例[J].陕西中医,1998:19(1):20.
[47]李庚和,中医为主治疗震颤麻痹症50例临床分析[J].上海中医药杂志,1992:(2):12.
[48]余德生,汪森.脑通防治帕金森氏病12例[J].辽宁中医杂志,1997:26(9):404.
[49]刘泰.震颇麻痹病110例辨证规律探讨[J].辽宁中医杂志,2002:29(2):82-83.
[50]邹忆怀.王永炎.治疗震颤病经验探讨[J].北京中医药大学学报,1996;19(4):15.
[51]徐尚华,宋淑卿.复方养血熄风汤治疗震颤麻痹病24例[J].浙江中医杂志,1994:29(12):534.
[52]王克勤.震颤麻痹的中医治疗[J].中医药研究,1991:(2):35.
[53]张小山.震颤麻痹证治[J].新中医,1997;29(6):60.
[54]王坤山,王慧艳.试谈震颤麻痹辨治体会[J].甘肃中医,1993;6(2):9.
[55]马济滨.补肾化痰通络治疗震颤性麻痹16例[J].陕西中医,2002;23(2):150.
[56]吴心兰.万希文.应用涤痰汤治疗震颤麻痹验案[J].辽宁中医杂志,1992;19(4):14.
[57]栗德远.架树永.老年颤证治疗四法[J].山东中医杂志,1993;12(4):12.
[58]王素蛾.辨证论治结合五虫散治疗老年性震颤麻痹[J].中级医刊,1992;27(11):59.
[59]邹亿怀,王永炎教授治疗颤振病(帕金森病)经验探析[J].北京中医药大学学报,1996:19(4):15-16.
[60]周英豪,胡建华.治疗震颤麻痹经验拾萃[J].上海中医药大学学报,2000;14(2):20.
[61]张莉,奚桂芳,贺伯民.头针和中药对帕金森病模型小鼠脑内抗氧化酶的影响[J].上海针灸杂志,1997;16(6):32-33.
[62]王亚丽,张学文.颤证病理机制及治疗的实验研究[J].陕西中医学院学报,1999:22(6):45-46.
[63]李如奎,赵虹,屠英梅.平颤汤对帕金森病模型动物行为和脑内多巴胺含量的影响[J].中医药研究,2000:16(2).39-41.
[64]赵虹,李如奎,陈丽娟.平颤汤治疗帕金森病临床与实验研究[J].上海中医药杂志,1999:(9):12-15.
[65]陈锡群.蔡定芳,郑振.养肝熄风方药对帕金森大鼠旋转行为的影响[J].上海中医药大学学报.2001;15(2):41-42.
[66]鲍远程,汪瀚,张波.抗震止痉胶囊对帕金森病作用机制的实验研究[J].中国中西医结合杂志,2001;21(3):193-195.
[67]小林恒靖.具有治疗帕金森病作用的天然物的筛选[日],国外医学中医中药分册.1999:21(6):23.
[68]象国章,孙宝存.左旋千金藤吮碱及其同类物作用于脑内多巴胺受体的研究进展[J].自然科学进展,1995;(5):55-63.
[69]金国章,陈丽娟,董兆君.左旋千金藤啶碱对DA受体的双重作用机制[J].药理学进展,1997:(10):9-18
[70]李如奎,陈丽娟.赵虹.左旋千金藤吮碱与澳隐亭合并治疗帕金森病[J].中国中西医结合杂志,1999:19(7):428-429.
[71]曹非.曹学兵,孙圣刚.银杏叶提取物对帕金森病大鼠黑质细胞的保护作用[J].复旦学报·医学科学版,2001:28(5):396-399.
[72]蔡定芳,陈锡群,高颖.补肾养肝方药对长期服用左旋多巴帕金森病大鼠黑质纹 状体功能的影响[J].中国中西医结合杂志,2002;22(1):43-46.
[73]部文,王丽娟,景朋.银杏叶提取物及银杏总内酷对帕金森病大鼠模型的作用[J].中国新药杂志,2002;9(7):458-461.
[74]王选伟.针刺治疗震颤麻痹40例[J].陕西中医,1994;(4):1761.
[75]张乃钲,韩旭华.针药结合治疗震颤麻痹临床观察中国针灸[J],1996;(2):11.
[76]陈利国.针刺治疗震颤麻痹40例临床观察[J].中医杂志,1996;37(4):2161.
[77]秦亮甫.针刺治疗震颤麻痹30例[J].上海针灸杂志,1989:(3):18.
[78]施孝文.温针治疗帕金森氏症21例[J].中国针灸,2004:24(1):241.
[79]张沛霖,张勤.针刺治疗震颤麻痹的临床观察[J].云南中医中药杂志,1996:17(5):39.
[80]唐大全.头针配梅花针治疗震颤麻痹12例[J].黑龙江中医药,1994;(3):491.
[81]郑翎,金宇.针刺治疗震颤麻痹52例临床观察[J].中国针灸,1998;18(2):791.
[82]张海波,张召平,许继平.电针治疗帕金森病50例临床观察[J].中国中西医结合杂志,1995;(4):246.
[83]王顺.周振坤,胡丙成.头部电针透穴疗法治疗帕金森氏病的临床研究[J].中国针灸,2003;23(3):1291.
[84]张海波,张召平,许继平.电针治疗帕金森病50例临床观察[J].中国中西医结合杂志,1995,(4):2461
[85]俞竹青.头皮针合四关穴为主治帕金森氏症[J].浙江中医学院学报,1994:18(6):45.
[86]王旭惠.针刺治疗帕金森病42例临床观察[J].第六届天津国际针灸临床学术汇编[C]12000174.
[87]张京峰,孙国胜.隔药灸神阙穴治疗帕金森病54例疗效观察[J].中国针灸,2005:25(9):611-612.
[88]张汗梁.祝维峰.针刺治疗帕金森病运动障碍的临床观察[J].中国针灸,2003:23(12):7091.
[89]唐大全.头针配梅花针治疗震颤麻痹12例[J].黑龙江中医药,1994:(3):49.
[90]刘帅洲.穴位注射配合头针治疗震颤麻痹17例[J].吉林中医药,2001:21(3):481.
[91]陶怀玉.电针加穴位注射治疗震颤麻痹42例临床观察[J].中国针灸.1989:(5):17.
[92]孙景涵.头皮针治疗带注射治疗震颤麻痹症10例[J].中国针灸,2002:22(8):5141.
[93]周学文.头针结合体针治疗震颤麻痹综合征38例[J].针灸临床杂志,1999; 15(10):411.
[94]蒋达树,刘家英,杨金洪.针药并用治疗震颤麻痹113例疗效观察[J].中医杂志,1990;(12):29.
[95]奚桂芳,蔡德亨,华雪桂,等.针刺加中药治疗帕金森氏病的临床疗效分析[J].上海针灸杂志,1995;14(6):243.
[96]周华青.针灸治疗帕金森病疗效观察[J].安徽中医临床杂志,2001:13(5):370.
[97]梁凤应,刘式祺.针刺配合药物治疗老年帕金森病55例[J].广西中医药,1997:20(5):34-35.
[98]奚桂芳,蔡德亨.头部穴位电刺激结合中药治疗帕金森氏病的临床研究[J].针刺研究,1997;105.
[99]李圣平.帕金森综合征的针灸康复疗法[J].四川中医,1993;(8):51.
[100]张颖清.全息生物学.中国高等教育出版社1989年版.
[101]王顺,周振坤,胡丙成.头部电针透穴疗法治疗帕金森氏病的临床研究[J].中国针灸,2003;23(3):129.
[102]奚桂芳,蔡德亨,陈国美,等.头部穴位电刺激对帕金森病震颤肌电位的影响[J].上海针灸杂志,1996:(3):5.
[103]王玲玲,何崇,刘跃光.针刺对帕金森病患者脑干诱发电位的影响[J]南京中医药大学学报,2000;16(4):229.
[104]张莉,奚桂芳,余慧贞.针刺结合中药对帕金森病血清抗氧化酶含量的影响[J].上海针灸杂志,1996;(6):3.
[105]董晓彤,王双昆,任小群.针刺治疗震颤麻痹对患者血中LPO和SOD含量的影响[J].针刺研究,2001:26(1):28.
[106]朱文昕,奚桂芳,睢久红.针药治疗对帕金森病小鼠脑内多巴胺影响[J].针刺研究,1997:88-89.
[107]徐斌,马聘,陈国志.针刺调节原发性帕金森病脑脊液中单胺类递质临床观察[J].中国针灸.2002:22(3):183.
[108]睢久红.奚桂芳,余爱珍.针刺结合复方中药治疗对帕金森病患者血浆中DA 含量的影响[J].针刺研究,1997:106-107.
[109]马骏,王华.电针帕金森模型大鼠对黑质TH含量的影响[J].针刺研究,2001;26(4):288.
[110]王玲玲,何崇,赵玫.针灸对帕金森病脑部血流状态的影响[J].中国针灸,1999;19(2):1151.
[111]马骏,田青.王彦青.电针对帕金森病大鼠纹状体谷氨酸含量的影响[J].上海针灸杂志,2003:22(1):361.
[112]Rohan de Silva HA,Khan NL,Wood NW The genetics of Parkinson's disease.Curr Opin Gen Dev,2000;10:292-298
[113]Reiss 0,Kuhn W,Krueger R.Genetic influence on the development of Parkinson's disease.J Neurol,2000:247 Suppl 2:69-74.
[114]Polymeropoulos MH,Higgins JJ,Golbe LI,et ai.Mapping of a gene for Parkinson' s disease to chromosome4 g21-q23.Science,1996;274(5290):1197-1199.
[115]Riedl AG Watts PM,Jenner P,et al.P450 enzymes and Parkinson's disease:the story so far.Mov Disord,1998;13(2):212-220.
[116]Wilhelmsen K.Mirei D,Marder K,et al.Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q132 Ann Neurol,1997;41(6):813-817.
[117]Waite LM,Broe GA,Creasey H,et al.Neurological signs,aging,and the neurodegenerative syndromes.Arch Neurol,1996;53(6):498-502.
[118]Dhandapani KM,Brann DW.Estrogen-astrocyte interactions:implications for neuroprotection.BMC Neurosci,2002;3(1):6—10.
[119]Langston J W,Forno L S,Tetrud J,et ai.Evidence of active nerve cell degeneration in the substantia nigra of humanns years after l-methyl-4-phenyi-2,3,6-tetrahydropyridine exposure.Ann Neural,1999;46(4):598-605.
[120]Tanner CM,Langston J W.Do environmental toxins cause Parkinson' s Disease A critical review.Neurology.1990;40(10 Suppl 3):suppl 17-30;discussion30-31.
[121]Perlmuter D.BrainRecovery.com:Powerful Therapy for Challenging Brain Disorders.Naples FL:The Perlmuter Heaalth Center (www.brainrecovery.com);2000;20 (1):235-236.
[122]Beal MF.Energetics in the pathogenesis of neurodegenerative diseases.Trends Neurosci,2000:23(7):298-304.
[123]LissB;Roeper J.Molecular physiology of neuronal K-ATP channels.Mol Membr Biol.2001;18(2).117-127.
[124]Ashcroft FM,Gribble FM.Correlating structure and function in ATP-sensitive K-channels.Trends Neurosci,1998;21 (7):28 8294.
[125]LissB,Roeper J.ATP-Sensitive potassium channels in dopaminergic Physiological Sciences,of 2001,16(5):214-217.
[126]Paik SR,Shin HJ,Lee JK.M,etal-catalyzed oxidation of alpha-synuciein in the presence of copper(Ⅱ) and hydrogen peroxide. Arch Biochem Biophys,2000;378(2):269-277.
[127]Masson J,Sagne C,Hamon M,et al,Neurotransmitter Transporters in the Central Nervous System.Pharmacological Reviews,1999:51(3):439-464.
[128]Phillis JW,RenJ,O 'Regan MH.Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex:studies withDL-threo-beta-benzyloxyaspartate.Brain Res,2000:880(1-2):224.
[129]Blandni F,Porter RH,Greenmaye JT.Glutamate and Parkinson's disease.Mol Neurobio,1996;12(1):73-94.
[130]Blandini F NappiG Tassorelli C,et al,Functional changes of the basal ganglia circuitry in Parkinson's disease.Progneurobiol,2000;62(1):63-88.
[131]Alagarsamy S,Sorensen SD,Conn PL Coordinate regulation of metabotropic glutamate receptors.Curr Opin Neurobiol,2001;11(3):357-362.
[132]Bruno V,Battaglia G;Casabona G,et al.Neuroprotection by,glial metabotropic glutamate receptors is mediated by transforming growth factor beta.J Neurosci,1998;18:9594-9600.
[133]Rouse ST,Marino MJ,Bradley SR,et al.Distribution and roles of metabotropic glutamate receptors in the basal ganglia motorn circuit:implications for treatment of Parkinson's Disease and related disorders.Pharcology and Therapeutics,2000:88(3):427-435.
[134]Dawson L,Chadha A,Megaiou M,et al.The group Ⅱ metabotropic glutamate receptor agonist,DCGIV,alleviates akinesia following intranigral or intraventricuiar administration in the reserpine-treatedrat.Br J Pharmacol,2002:129(3):541-546.
[135]Mardery K,Tang MX,Cote L,etal.The frequency and associated risk factors for dementia in patients with Parkinson's disease.Arch Neurol,1995,52:695-701.
[136]马建军,孙翠萍,李德霞,等.帕金森病患者的智能及事件相关电位研究[J].中华老年医学杂志,1996:15:97-100.
[137]Tsai CH.L u CS.Hua M S.er al.Cognitive dysfunction in early onset parkisonism.Acta Neurol Scand,1994;89:9-14.
[138]Caparros-lefebvre D,PecheuxN,PetitV,et al.Which factors predict cognitived ecline in Parkinson's disease? JNeurol Neurosurg Psychiatry,1995;58:51-55.
[139]Cummings JL.Depression and Parkinson's disease:a review.Am J Psychiatry,1992:149:4 43-454.
[140]MorganJ,Sethi KD.LevodoPa and the Progression of Parkinson' s disease.Curr Neurol Neuorsci ReP,2005:5(4):261-262.
[141]Stocchi F,Vacca LRuggieri S,et al.Intermittent vs continuous ievodoPaadministration in Patients with advanced Parkinson disease:a clinical andPhamracokinetic study.Arch Neurol,2005:62(6):905-910.
[142]CamardaR,Camarda C,Grimaldi S,et al.Effects of levodopa oral bolus on the kinematics of the Pointing movements in Parkinson' s disease Patients.J Neurol,2005:252(9):1074-1081.
[143]Walton-HadlockJL.LevodoPa and the Progression of parkinson' s disease ·N Engi JMed,2005;352(13):1386-1389.
[144]Mercuri NB,Bemardi G.The' magic' of L-doPa:why is it the gold standard Pakinson·s disease therapy? Trends Pharmacol sci,2005:26(7):341-344.
[145]RajdaC,DiboG,Vecsei L,et ai.increased dopamine content in Iymphocytes from high-dose L-DoPa-treated Parkinson' s diseas Patients.Neuroimmunomodulation,2005:12(2):81-84.
[146]Ucar G,Gokhan N,Yesilada A,et al 1-N-Substituted thiocarbamoyl-3-Phenyl-5-thienyl-2-Pyrazolines:a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson' s and Alzheimer s diseases.NeurosciLett,2005:382(3):327-331.
[147]igosheva N,LorzC,o,Conner E,etal Isatin.an endogenous monoamine oxidase inhibitor,triggers a dose-and time-dependent switch from apoptosis to necorsis in huma neuorblastoma cells.Neurochem int,2005;47(3):216-224.
[148]MacleodAD,Counsell CE,Ires N,et al Monoamine oxidase E inhibitors for early Parkinson' s disease.Cochrane Database syst Rev,2005;(3):CD004898.
[149]JennerP,Rotigotine.A novel dopamine agonist for the transdermal treatment Of parkinson' s disease.Neurology,2005:65(2Suppl 1):3-5.
[150]Singh A,ilthoff R,Martineau RJ,et al.pramipexole,ropinirole,and mania in Parkinson's disease.Am J Psychiatry,2005;162(4):814-815.
[151]PanT,xie w,Jankovic J,et al,Biological effects of pramipexoie on dopaminergic neuron-associated genes:relevanceton neuroportection. Neurosci Lett,2005:377(2):106-109.
[152]Moller JC,oertel wH.Koster J,et al.allong-term efficacy and safety of Pramipexole in advanced parkinson' s disease:results from a Europeanmulticenter trial.Mov Disord,2005:20(5):602-610.
[153]Navan p,Findley U,Undy MB,et al A randomly assigned double-blind cross-over study examining the relative anti-Parkinsonian tremor effcts of Pramipexole and Pergolide EurJ Neuorl,2005;12(1):1-8.
[154]Tintner R,Manian P,Gauthier P,et al Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.Arch Neuorl,2005:62(8):1290-1295.
[155]Storch A,Trenkwalder C,OehlweinC,et al High-dose treatment with Pergolide in parkinson' s disease Patients with motor fluctuations and dyskinesias,parkinsonism Relat Disord,2005:11(6):393-398.
[156]Thalamas C,Rajmanl,KulisevskyJ,et al Pergolide:Pharmacokineticsin Patients with mildtomoderate Parkinson multiple-dose disease Clin Neurophamracol,2005;28(3):120-125.
[157]GrossetK,Grosset D,LeesA,et al Trial of subtherapeutic Pergolide in denovo Parkinson' s disease Mov Disord,2005;20(3):363-366.
[158]Widnell KL,Cornelia C.Role of C0MT inhibitors and dopamine agonists in the treatment of motor fluctuations.Mov Disord,2005;(SuPPl 11):30-37.
[159]Keating GM,Lyseng-Williamson KA.Tolcapone:a review of its use in themanagement of Parkinson' s disease.CNSDrugs,2005;19(2):165-184.
[160]Findley U,LeesA,Apajasalo M,et ai Cost-efectiveness of levodopa/carbidopa/entacapone(Stalevo)compared to standard care in UK Parkinson' s disease patients with wearing-off Curr Med Res OPin,2005:21(7):1005-1014.
[161]Roller W.Guarnieri M,Hubble J.et ai.An open-label evaluation of the tolerability and safety of stalevo(carbidopa,levodopa and entacapone) in Pakrinson' s disease patients experiencing wearing-off J Neural Transm,2005;112(2):221-230.
[162]Reichmann H,Boas J,Macmahon D,et ai EEicacy of combining levodopa with entacaDone on aualitv of life and activities of daily livingin Patients experiencing wearing-off type fluctuations.Acta Neurol scand,2005;111(1):21-28.
[163]Schrag A.Entacapone in the treatment of Parkinson' s disease.Lancet Neuorl,2005;4(6):366-370.
[164]Valkovic P,Benetin J,Blazicek p,et al.Reduced Plasma homocysteine levels in levodoPa /entacapone treated Parkinson Patients.Parkinsonism Relat Disord,2005;11(4):253-256.
[165]paija 0,Laine K,Kultalahti ER,et al.Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.Clin Neuropharmacol.2005;28(3):115-119.
[166]BrooksDJ,Agid Y,Eggert K,et al Treatment of end-of-dose wearing off in Parkinson' s disease:stalevo (levodopa/carbidopa/entacapone) and levodopa / DDCI given in combination with Comtess /Comtan (entacapone)Provide equivalent improvements in symptom control superior to that of Traditional levodopa/DDCI treatment.Eur Neuorl,2005;53(4):197-202.
[167]SchaPira A,Bate G,Krkpatrick P.Rasagiline.Nat Rev Drug Discov,2005:4(8):625-626.
[168]Youdim MB.Fridkin M,Zheng H Bifunctional drug derivatives of MA0-B inhibitor rasagiline and iorn chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.Mech Ageing Dev,2005:126(2):317-326.
[170]Siddiqui MA,plosker GL.Rasagiline.Drugs Aging,2005;22(1):83-91.
[171]Parkinson Study GrouP.A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations:the PRESTO study.Arch Neuorl,2005;62(2):241-248.
[172]Rascol 0,Brooks DJ,Melamed E,et al.Rasagiline as an adjunct to levodopa in patients with Parkinson' s disease and motor fluctuations(LARGO,Lasting effct in Adjunct therapy with Rasagiline Given Once daily,study):a randomised,double-blind,Parallel-group trial.Lancet.2005;365(9463):947-954.
[173]Clarke CE Rasagiline for motor complications in parkinson' s disease.Lancet,2005:365(9463):914-916.
[174]Youdim MB,Bar Ammo,Yogev-Falach M,et al Rasagiline:neurodegeneration,neuroportection,and mitochondrial permeability transitionj Neurosci Res,2005;79(1-2):172-179.
[175]Parkinson study GrouP.Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.Brain Res Brain ResRev,2005;48(2):379-387.
[176]刘焯霞.帕金森病诊断标准中华神经外科杂志.2002;18(1):6.
[177]梁希彬,等.电针治疗部分损伤帕金森病大鼠的实验研究[J].针刺研究.2001:26(3):209.
[178]董晓彤,等.针刺治疗震颇麻痹对患者血中LPO和50D含量的影响[J].针刺研究2001:26(1):28.
[179]奚桂芳,等.头部穴位电刺激对帕金森病震颇肌电位的影响[J].上海针灸杂志.1996:15(3):5.
[3]孙星衍.校华氏中藏经,第1版.上海:商务印书馆,1956;25.
[4]孙思邈.备急千金要方(影印本)北京:人民卫生出版社,1982;158.
[5]孙一奎.赤水玄珠.北京:人民卫生出版社,1986;1125.
[6]清·张璐.张氏医通.中国中医药出版社,1995;141,268,345,464-465.
[7]王肯堂.证治准绳.北京:人民卫生出版社,1991;435-437,578-580.
[8]王永炎,李明富,戴锡孟,等编.中医内科学[M].上海:上海科学技术出版社.1994;第6版:370.
[9]王亚丽.颤证的病因病机探讨[J].陕西中医学院学报,1995;21(3):5.
[10]朱红梅,震颤麻痹的病理探析[J].厦门大学学报.自然科学版,2000;(64):556-559.
[11]邹忆怀.王永炎.治疗颤振病(帕金森氏病)经验探讨[J].北京中医药大学学报,1996:(19):15.
[12]黄俊山.震颤麻痹辨证体会[J].实用中西医结合杂志,1996:9(1):8.
[13]潘澄镰.震颤麻痹的证治探讨[J].浙江中医杂志.1990:25(11):483.
[14]陈利国.针刺治疗震颇麻痹49例临床观察[J].中医杂志,1996:37(4):217.
[15]崔悦.解郁法为土治疗震颤麻痹12例[J],国医论坛,1993;8(5):37.
[16]王坤山,等.试谈A颤麻痹辨治体会[J],甘肃中医,1993;6(3):9.
[17]周叔平.浅谈震颤麻痹综合征与督脉的关系[J].新中医,1997;29(5):52.
[18]李学文.中医辨证分型治疗震颤麻痹症的临床体会[J].包头医学.2000;24(3):28.
[19]黄文燕,眼针结合中药治疗帕金森病45例[J].上海针灸杂志,2000;19(4):20.
[20]景晓东,张海峰,朗丽辉.定振丸治疗震颤麻痹34例[J].吉林中医药,2000:(1):38.
[21]劳国平.中西医结合治疗震颤麻痹的疗效观察[J].河北中医,2000;22(10):777-778.
[22]陈建宗,江文,史健,等.培补肝肾为主治疗帕金森病临床观察[J].成都中医药大学学,1999:22(3):14-19.
[23]刘尚建.中西医结合治疗老年颤证26例[J].陕西中医,2001;22(3):172.
[24]丰广魁.震颤舒治疗帕金森病30例[J].陕西中医,2000:21(11):481.
[25]郭淑睿,张彩玉,付文玉,等.坎离丸治疗帕金森病19例[J].辽宁中医杂志,2001;28(3):154-155.
[26]叶中峰.辨证分型治疗震颤麻痹36例[J].四川中医,2001;19(10):30.
[27]祝维峰.震颤宁与美多巴合用治疗帕金森病40例[J].中国民间疗法,2000:8(7):35-36.
[28]张健.中药治疗帕金森氏综合征30例[J].中医药信息,2000:(3):73.
[29]王建国,罗文辉.唐世清.乌龙汤治疗震颤麻痹22例小结[J].湖南中医杂志,2000;16(1):13-14.
[30]陈建宗,陈晓莉,李军昌.培补肝肾法治疗帕金森病40例临床观察[J].中医药研究,1998:14(3):10.
[31]樊奎.周仲瑛.治疗震颤麻痹的经验[J].中医杂志,1996;37(11):63-64.
[32]王克勤.震颤麻痹的中医治疗[J].中医药研究,199l;(2):35.
[33]刘明武.震颤麻痹辨治探幽[J].辽宁中医杂志,1997;24(11):490.
[34]曾宪贵.育阴活络汤治疗四肢震颤4例[J].辽宁中医杂志,1990;17(6):16.
[35]王瑞海.震颤证临床治疗概述[J].山东中医杂志,1990;9(1):57.
[36]潘文奎.小议帕金森氏病的证治思路[J].中医药研究,1995:(6):9.
[37]黄月芳.中西医结合治疗震颤麻痹32例[J].江苏中医,1997,18(9):16.
[38]李双蕾.中西医结合治疗震颤麻痹临床观察[J].广西中医药.1997;20(3):25.
[39]刘华中西医结合治疗帕金森氏病45例[J].浙江中医杂志,1993;28(6):47.
[40]任光兴.熄风汤、安坦治疗帕金森氏病综合征对照观察[J].山东中医杂志,1990:9(2):21.
[41]李玉生.内外结合治疗震颇麻痹42例[J].陕西中医,1993;14(8):348.
[42]丰广魁.邵凤扬,李加兵.中药震颇舒治疗震颇麻痹的疗效分析[J].中国临床康复,2002;6(3):334-335.
[43]黄俊山.震颇麻痹辨证体会[J].实用中西医结合杂志,1996;9(1):8.
[44]王克勤.震颤麻痹的中医治疗[J].中医药研究,1991;(2):35.
[45]黄俊山.震颤麻痹辨治体会[J].实用中西医结合杂志,1996;9(1):8-9.
[46]秦有学.中西医结合治疗震颤麻痹31例[J].陕西中医,1998:19(1):20.
[47]李庚和,中医为主治疗震颤麻痹症50例临床分析[J].上海中医药杂志,1992:(2):12.
[48]余德生,汪森.脑通防治帕金森氏病12例[J].辽宁中医杂志,1997:26(9):404.
[49]刘泰.震颇麻痹病110例辨证规律探讨[J].辽宁中医杂志,2002:29(2):82-83.
[50]邹忆怀.王永炎.治疗震颤病经验探讨[J].北京中医药大学学报,1996;19(4):15.
[51]徐尚华,宋淑卿.复方养血熄风汤治疗震颤麻痹病24例[J].浙江中医杂志,1994:29(12):534.
[52]王克勤.震颤麻痹的中医治疗[J].中医药研究,1991:(2):35.
[53]张小山.震颤麻痹证治[J].新中医,1997;29(6):60.
[54]王坤山,王慧艳.试谈震颤麻痹辨治体会[J].甘肃中医,1993;6(2):9.
[55]马济滨.补肾化痰通络治疗震颤性麻痹16例[J].陕西中医,2002;23(2):150.
[56]吴心兰.万希文.应用涤痰汤治疗震颤麻痹验案[J].辽宁中医杂志,1992;19(4):14.
[57]栗德远.架树永.老年颤证治疗四法[J].山东中医杂志,1993;12(4):12.
[58]王素蛾.辨证论治结合五虫散治疗老年性震颤麻痹[J].中级医刊,1992;27(11):59.
[59]邹亿怀,王永炎教授治疗颤振病(帕金森病)经验探析[J].北京中医药大学学报,1996:19(4):15-16.
[60]周英豪,胡建华.治疗震颤麻痹经验拾萃[J].上海中医药大学学报,2000;14(2):20.
[61]张莉,奚桂芳,贺伯民.头针和中药对帕金森病模型小鼠脑内抗氧化酶的影响[J].上海针灸杂志,1997;16(6):32-33.
[62]王亚丽,张学文.颤证病理机制及治疗的实验研究[J].陕西中医学院学报,1999:22(6):45-46.
[63]李如奎,赵虹,屠英梅.平颤汤对帕金森病模型动物行为和脑内多巴胺含量的影响[J].中医药研究,2000:16(2).39-41.
[64]赵虹,李如奎,陈丽娟.平颤汤治疗帕金森病临床与实验研究[J].上海中医药杂志,1999:(9):12-15.
[65]陈锡群.蔡定芳,郑振.养肝熄风方药对帕金森大鼠旋转行为的影响[J].上海中医药大学学报.2001;15(2):41-42.
[66]鲍远程,汪瀚,张波.抗震止痉胶囊对帕金森病作用机制的实验研究[J].中国中西医结合杂志,2001;21(3):193-195.
[67]小林恒靖.具有治疗帕金森病作用的天然物的筛选[日],国外医学中医中药分册.1999:21(6):23.
[68]象国章,孙宝存.左旋千金藤吮碱及其同类物作用于脑内多巴胺受体的研究进展[J].自然科学进展,1995;(5):55-63.
[69]金国章,陈丽娟,董兆君.左旋千金藤啶碱对DA受体的双重作用机制[J].药理学进展,1997:(10):9-18
[70]李如奎,陈丽娟.赵虹.左旋千金藤吮碱与澳隐亭合并治疗帕金森病[J].中国中西医结合杂志,1999:19(7):428-429.
[71]曹非.曹学兵,孙圣刚.银杏叶提取物对帕金森病大鼠黑质细胞的保护作用[J].复旦学报·医学科学版,2001:28(5):396-399.
[72]蔡定芳,陈锡群,高颖.补肾养肝方药对长期服用左旋多巴帕金森病大鼠黑质纹 状体功能的影响[J].中国中西医结合杂志,2002;22(1):43-46.
[73]部文,王丽娟,景朋.银杏叶提取物及银杏总内酷对帕金森病大鼠模型的作用[J].中国新药杂志,2002;9(7):458-461.
[74]王选伟.针刺治疗震颤麻痹40例[J].陕西中医,1994;(4):1761.
[75]张乃钲,韩旭华.针药结合治疗震颤麻痹临床观察中国针灸[J],1996;(2):11.
[76]陈利国.针刺治疗震颤麻痹40例临床观察[J].中医杂志,1996;37(4):2161.
[77]秦亮甫.针刺治疗震颤麻痹30例[J].上海针灸杂志,1989:(3):18.
[78]施孝文.温针治疗帕金森氏症21例[J].中国针灸,2004:24(1):241.
[79]张沛霖,张勤.针刺治疗震颤麻痹的临床观察[J].云南中医中药杂志,1996:17(5):39.
[80]唐大全.头针配梅花针治疗震颤麻痹12例[J].黑龙江中医药,1994;(3):491.
[81]郑翎,金宇.针刺治疗震颤麻痹52例临床观察[J].中国针灸,1998;18(2):791.
[82]张海波,张召平,许继平.电针治疗帕金森病50例临床观察[J].中国中西医结合杂志,1995;(4):246.
[83]王顺.周振坤,胡丙成.头部电针透穴疗法治疗帕金森氏病的临床研究[J].中国针灸,2003;23(3):1291.
[84]张海波,张召平,许继平.电针治疗帕金森病50例临床观察[J].中国中西医结合杂志,1995,(4):2461
[85]俞竹青.头皮针合四关穴为主治帕金森氏症[J].浙江中医学院学报,1994:18(6):45.
[86]王旭惠.针刺治疗帕金森病42例临床观察[J].第六届天津国际针灸临床学术汇编[C]12000174.
[87]张京峰,孙国胜.隔药灸神阙穴治疗帕金森病54例疗效观察[J].中国针灸,2005:25(9):611-612.
[88]张汗梁.祝维峰.针刺治疗帕金森病运动障碍的临床观察[J].中国针灸,2003:23(12):7091.
[89]唐大全.头针配梅花针治疗震颤麻痹12例[J].黑龙江中医药,1994:(3):49.
[90]刘帅洲.穴位注射配合头针治疗震颤麻痹17例[J].吉林中医药,2001:21(3):481.
[91]陶怀玉.电针加穴位注射治疗震颤麻痹42例临床观察[J].中国针灸.1989:(5):17.
[92]孙景涵.头皮针治疗带注射治疗震颤麻痹症10例[J].中国针灸,2002:22(8):5141.
[93]周学文.头针结合体针治疗震颤麻痹综合征38例[J].针灸临床杂志,1999; 15(10):411.
[94]蒋达树,刘家英,杨金洪.针药并用治疗震颤麻痹113例疗效观察[J].中医杂志,1990;(12):29.
[95]奚桂芳,蔡德亨,华雪桂,等.针刺加中药治疗帕金森氏病的临床疗效分析[J].上海针灸杂志,1995;14(6):243.
[96]周华青.针灸治疗帕金森病疗效观察[J].安徽中医临床杂志,2001:13(5):370.
[97]梁凤应,刘式祺.针刺配合药物治疗老年帕金森病55例[J].广西中医药,1997:20(5):34-35.
[98]奚桂芳,蔡德亨.头部穴位电刺激结合中药治疗帕金森氏病的临床研究[J].针刺研究,1997;105.
[99]李圣平.帕金森综合征的针灸康复疗法[J].四川中医,1993;(8):51.
[100]张颖清.全息生物学.中国高等教育出版社1989年版.
[101]王顺,周振坤,胡丙成.头部电针透穴疗法治疗帕金森氏病的临床研究[J].中国针灸,2003;23(3):129.
[102]奚桂芳,蔡德亨,陈国美,等.头部穴位电刺激对帕金森病震颤肌电位的影响[J].上海针灸杂志,1996:(3):5.
[103]王玲玲,何崇,刘跃光.针刺对帕金森病患者脑干诱发电位的影响[J]南京中医药大学学报,2000;16(4):229.
[104]张莉,奚桂芳,余慧贞.针刺结合中药对帕金森病血清抗氧化酶含量的影响[J].上海针灸杂志,1996;(6):3.
[105]董晓彤,王双昆,任小群.针刺治疗震颤麻痹对患者血中LPO和SOD含量的影响[J].针刺研究,2001:26(1):28.
[106]朱文昕,奚桂芳,睢久红.针药治疗对帕金森病小鼠脑内多巴胺影响[J].针刺研究,1997:88-89.
[107]徐斌,马聘,陈国志.针刺调节原发性帕金森病脑脊液中单胺类递质临床观察[J].中国针灸.2002:22(3):183.
[108]睢久红.奚桂芳,余爱珍.针刺结合复方中药治疗对帕金森病患者血浆中DA 含量的影响[J].针刺研究,1997:106-107.
[109]马骏,王华.电针帕金森模型大鼠对黑质TH含量的影响[J].针刺研究,2001;26(4):288.
[110]王玲玲,何崇,赵玫.针灸对帕金森病脑部血流状态的影响[J].中国针灸,1999;19(2):1151.
[111]马骏,田青.王彦青.电针对帕金森病大鼠纹状体谷氨酸含量的影响[J].上海针灸杂志,2003:22(1):361.
[112]Rohan de Silva HA,Khan NL,Wood NW The genetics of Parkinson's disease.Curr Opin Gen Dev,2000;10:292-298
[113]Reiss 0,Kuhn W,Krueger R.Genetic influence on the development of Parkinson's disease.J Neurol,2000:247 Suppl 2:69-74.
[114]Polymeropoulos MH,Higgins JJ,Golbe LI,et ai.Mapping of a gene for Parkinson' s disease to chromosome4 g21-q23.Science,1996;274(5290):1197-1199.
[115]Riedl AG Watts PM,Jenner P,et al.P450 enzymes and Parkinson's disease:the story so far.Mov Disord,1998;13(2):212-220.
[116]Wilhelmsen K.Mirei D,Marder K,et al.Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q132 Ann Neurol,1997;41(6):813-817.
[117]Waite LM,Broe GA,Creasey H,et al.Neurological signs,aging,and the neurodegenerative syndromes.Arch Neurol,1996;53(6):498-502.
[118]Dhandapani KM,Brann DW.Estrogen-astrocyte interactions:implications for neuroprotection.BMC Neurosci,2002;3(1):6—10.
[119]Langston J W,Forno L S,Tetrud J,et ai.Evidence of active nerve cell degeneration in the substantia nigra of humanns years after l-methyl-4-phenyi-2,3,6-tetrahydropyridine exposure.Ann Neural,1999;46(4):598-605.
[120]Tanner CM,Langston J W.Do environmental toxins cause Parkinson' s Disease A critical review.Neurology.1990;40(10 Suppl 3):suppl 17-30;discussion30-31.
[121]Perlmuter D.BrainRecovery.com:Powerful Therapy for Challenging Brain Disorders.Naples FL:The Perlmuter Heaalth Center (www.brainrecovery.com);2000;20 (1):235-236.
[122]Beal MF.Energetics in the pathogenesis of neurodegenerative diseases.Trends Neurosci,2000:23(7):298-304.
[123]LissB;Roeper J.Molecular physiology of neuronal K-ATP channels.Mol Membr Biol.2001;18(2).117-127.
[124]Ashcroft FM,Gribble FM.Correlating structure and function in ATP-sensitive K-channels.Trends Neurosci,1998;21 (7):28 8294.
[125]LissB,Roeper J.ATP-Sensitive potassium channels in dopaminergic Physiological Sciences,of 2001,16(5):214-217.
[126]Paik SR,Shin HJ,Lee JK.M,etal-catalyzed oxidation of alpha-synuciein in the presence of copper(Ⅱ) and hydrogen peroxide. Arch Biochem Biophys,2000;378(2):269-277.
[127]Masson J,Sagne C,Hamon M,et al,Neurotransmitter Transporters in the Central Nervous System.Pharmacological Reviews,1999:51(3):439-464.
[128]Phillis JW,RenJ,O 'Regan MH.Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex:studies withDL-threo-beta-benzyloxyaspartate.Brain Res,2000:880(1-2):224.
[129]Blandni F,Porter RH,Greenmaye JT.Glutamate and Parkinson's disease.Mol Neurobio,1996;12(1):73-94.
[130]Blandini F NappiG Tassorelli C,et al,Functional changes of the basal ganglia circuitry in Parkinson's disease.Progneurobiol,2000;62(1):63-88.
[131]Alagarsamy S,Sorensen SD,Conn PL Coordinate regulation of metabotropic glutamate receptors.Curr Opin Neurobiol,2001;11(3):357-362.
[132]Bruno V,Battaglia G;Casabona G,et al.Neuroprotection by,glial metabotropic glutamate receptors is mediated by transforming growth factor beta.J Neurosci,1998;18:9594-9600.
[133]Rouse ST,Marino MJ,Bradley SR,et al.Distribution and roles of metabotropic glutamate receptors in the basal ganglia motorn circuit:implications for treatment of Parkinson's Disease and related disorders.Pharcology and Therapeutics,2000:88(3):427-435.
[134]Dawson L,Chadha A,Megaiou M,et al.The group Ⅱ metabotropic glutamate receptor agonist,DCGIV,alleviates akinesia following intranigral or intraventricuiar administration in the reserpine-treatedrat.Br J Pharmacol,2002:129(3):541-546.
[135]Mardery K,Tang MX,Cote L,etal.The frequency and associated risk factors for dementia in patients with Parkinson's disease.Arch Neurol,1995,52:695-701.
[136]马建军,孙翠萍,李德霞,等.帕金森病患者的智能及事件相关电位研究[J].中华老年医学杂志,1996:15:97-100.
[137]Tsai CH.L u CS.Hua M S.er al.Cognitive dysfunction in early onset parkisonism.Acta Neurol Scand,1994;89:9-14.
[138]Caparros-lefebvre D,PecheuxN,PetitV,et al.Which factors predict cognitived ecline in Parkinson's disease? JNeurol Neurosurg Psychiatry,1995;58:51-55.
[139]Cummings JL.Depression and Parkinson's disease:a review.Am J Psychiatry,1992:149:4 43-454.
[140]MorganJ,Sethi KD.LevodoPa and the Progression of Parkinson' s disease.Curr Neurol Neuorsci ReP,2005:5(4):261-262.
[141]Stocchi F,Vacca LRuggieri S,et al.Intermittent vs continuous ievodoPaadministration in Patients with advanced Parkinson disease:a clinical andPhamracokinetic study.Arch Neurol,2005:62(6):905-910.
[142]CamardaR,Camarda C,Grimaldi S,et al.Effects of levodopa oral bolus on the kinematics of the Pointing movements in Parkinson' s disease Patients.J Neurol,2005:252(9):1074-1081.
[143]Walton-HadlockJL.LevodoPa and the Progression of parkinson' s disease ·N Engi JMed,2005;352(13):1386-1389.
[144]Mercuri NB,Bemardi G.The' magic' of L-doPa:why is it the gold standard Pakinson·s disease therapy? Trends Pharmacol sci,2005:26(7):341-344.
[145]RajdaC,DiboG,Vecsei L,et ai.increased dopamine content in Iymphocytes from high-dose L-DoPa-treated Parkinson' s diseas Patients.Neuroimmunomodulation,2005:12(2):81-84.
[146]Ucar G,Gokhan N,Yesilada A,et al 1-N-Substituted thiocarbamoyl-3-Phenyl-5-thienyl-2-Pyrazolines:a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson' s and Alzheimer s diseases.NeurosciLett,2005:382(3):327-331.
[147]igosheva N,LorzC,o,Conner E,etal Isatin.an endogenous monoamine oxidase inhibitor,triggers a dose-and time-dependent switch from apoptosis to necorsis in huma neuorblastoma cells.Neurochem int,2005;47(3):216-224.
[148]MacleodAD,Counsell CE,Ires N,et al Monoamine oxidase E inhibitors for early Parkinson' s disease.Cochrane Database syst Rev,2005;(3):CD004898.
[149]JennerP,Rotigotine.A novel dopamine agonist for the transdermal treatment Of parkinson' s disease.Neurology,2005:65(2Suppl 1):3-5.
[150]Singh A,ilthoff R,Martineau RJ,et al.pramipexole,ropinirole,and mania in Parkinson's disease.Am J Psychiatry,2005;162(4):814-815.
[151]PanT,xie w,Jankovic J,et al,Biological effects of pramipexoie on dopaminergic neuron-associated genes:relevanceton neuroportection. Neurosci Lett,2005:377(2):106-109.
[152]Moller JC,oertel wH.Koster J,et al.allong-term efficacy and safety of Pramipexole in advanced parkinson' s disease:results from a Europeanmulticenter trial.Mov Disord,2005:20(5):602-610.
[153]Navan p,Findley U,Undy MB,et al A randomly assigned double-blind cross-over study examining the relative anti-Parkinsonian tremor effcts of Pramipexole and Pergolide EurJ Neuorl,2005;12(1):1-8.
[154]Tintner R,Manian P,Gauthier P,et al Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.Arch Neuorl,2005:62(8):1290-1295.
[155]Storch A,Trenkwalder C,OehlweinC,et al High-dose treatment with Pergolide in parkinson' s disease Patients with motor fluctuations and dyskinesias,parkinsonism Relat Disord,2005:11(6):393-398.
[156]Thalamas C,Rajmanl,KulisevskyJ,et al Pergolide:Pharmacokineticsin Patients with mildtomoderate Parkinson multiple-dose disease Clin Neurophamracol,2005;28(3):120-125.
[157]GrossetK,Grosset D,LeesA,et al Trial of subtherapeutic Pergolide in denovo Parkinson' s disease Mov Disord,2005;20(3):363-366.
[158]Widnell KL,Cornelia C.Role of C0MT inhibitors and dopamine agonists in the treatment of motor fluctuations.Mov Disord,2005;(SuPPl 11):30-37.
[159]Keating GM,Lyseng-Williamson KA.Tolcapone:a review of its use in themanagement of Parkinson' s disease.CNSDrugs,2005;19(2):165-184.
[160]Findley U,LeesA,Apajasalo M,et ai Cost-efectiveness of levodopa/carbidopa/entacapone(Stalevo)compared to standard care in UK Parkinson' s disease patients with wearing-off Curr Med Res OPin,2005:21(7):1005-1014.
[161]Roller W.Guarnieri M,Hubble J.et ai.An open-label evaluation of the tolerability and safety of stalevo(carbidopa,levodopa and entacapone) in Pakrinson' s disease patients experiencing wearing-off J Neural Transm,2005;112(2):221-230.
[162]Reichmann H,Boas J,Macmahon D,et ai EEicacy of combining levodopa with entacaDone on aualitv of life and activities of daily livingin Patients experiencing wearing-off type fluctuations.Acta Neurol scand,2005;111(1):21-28.
[163]Schrag A.Entacapone in the treatment of Parkinson' s disease.Lancet Neuorl,2005;4(6):366-370.
[164]Valkovic P,Benetin J,Blazicek p,et al.Reduced Plasma homocysteine levels in levodoPa /entacapone treated Parkinson Patients.Parkinsonism Relat Disord,2005;11(4):253-256.
[165]paija 0,Laine K,Kultalahti ER,et al.Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.Clin Neuropharmacol.2005;28(3):115-119.
[166]BrooksDJ,Agid Y,Eggert K,et al Treatment of end-of-dose wearing off in Parkinson' s disease:stalevo (levodopa/carbidopa/entacapone) and levodopa / DDCI given in combination with Comtess /Comtan (entacapone)Provide equivalent improvements in symptom control superior to that of Traditional levodopa/DDCI treatment.Eur Neuorl,2005;53(4):197-202.
[167]SchaPira A,Bate G,Krkpatrick P.Rasagiline.Nat Rev Drug Discov,2005:4(8):625-626.
[168]Youdim MB.Fridkin M,Zheng H Bifunctional drug derivatives of MA0-B inhibitor rasagiline and iorn chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.Mech Ageing Dev,2005:126(2):317-326.
[170]Siddiqui MA,plosker GL.Rasagiline.Drugs Aging,2005;22(1):83-91.
[171]Parkinson Study GrouP.A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations:the PRESTO study.Arch Neuorl,2005;62(2):241-248.
[172]Rascol 0,Brooks DJ,Melamed E,et al.Rasagiline as an adjunct to levodopa in patients with Parkinson' s disease and motor fluctuations(LARGO,Lasting effct in Adjunct therapy with Rasagiline Given Once daily,study):a randomised,double-blind,Parallel-group trial.Lancet.2005;365(9463):947-954.
[173]Clarke CE Rasagiline for motor complications in parkinson' s disease.Lancet,2005:365(9463):914-916.
[174]Youdim MB,Bar Ammo,Yogev-Falach M,et al Rasagiline:neurodegeneration,neuroportection,and mitochondrial permeability transitionj Neurosci Res,2005;79(1-2):172-179.
[175]Parkinson study GrouP.Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.Brain Res Brain ResRev,2005;48(2):379-387.
[176]刘焯霞.帕金森病诊断标准中华神经外科杂志.2002;18(1):6.
[177]梁希彬,等.电针治疗部分损伤帕金森病大鼠的实验研究[J].针刺研究.2001:26(3):209.
[178]董晓彤,等.针刺治疗震颇麻痹对患者血中LPO和50D含量的影响[J].针刺研究2001:26(1):28.
[179]奚桂芳,等.头部穴位电刺激对帕金森病震颇肌电位的影响[J].上海针灸杂志.1996:15(3):5.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |